Central administration of dopamine D3 receptor antisense to rat: Effects on locomotion, dopamine release and [3H]spiperone binding

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 358, Issue 3, 1998, Pages 342-350

  Ekman, Agneta ^a   Nissbrandt, Hans ^a   Heilig, Markus ^b   Dijkstra, Durk ^c   Eriksson, Elias ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antisense; Behaviour; Dopamine; Dopamine D3 receptor; In vive microdialysis; Radioligand binding

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOPAMINE; DOPAMINE 3 RECEPTOR; MESSENGER RNA; RADIOLIGAND; SPIPERONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FOREBRAIN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; MICRODIALYSIS; MONOLAYER CULTURE; NONHUMAN; NUCLEUS ACCUMBENS; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY;

ANIMALS; BINDING SITES; BRAIN; CELLS, CULTURED; CHO CELLS; CRICETINAE; DOPAMINE; DOPAMINE ANTAGONISTS; LOCOMOTION; MALE; MICRODIALYSIS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPIPERONE;

EID: 0031665791     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005263     Document Type: Article

References (71)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949
2. 3 receptor ligands. Eur J Pharmacol 281:R7-R9
3. 3 receptor-selective ligand, 7-OH-DPAT, in normal and the reserpine-treated rat. Eur J Pharmacol 260:177-181
4. 3 receptor agonist ligand, to CHO-K1 cells. Life Sci 57:1401-1410
5. Andersen PH (1988) Differential effects of EEDQ on the dopamine D-1 receptor in vivo and in vitro. Eur J Pharmacol 152:153-156
6. Aretha CW, Sinha A, Galloway MP (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther 274:609-613
7. Ariano MA, Sibley DR (1994) Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Res 649:95-110
8. 2 receptor mRNA. Brain Res 564:203-219
9. Burch, RM, Mahan LC (1991) Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. J Clin Invest 88:1190-1196
10. Bürgisser E (1984) Radioligand-receptor binding studies: what's wrong with the Scatchard analysis? Trends Pharmacol Sci 5:142-144
11. 3 dopamine receptors. Neuropsychopharmacology 12:335-345
12. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D3 receptors. Science 260:1814-1816
13. Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437-440
14. Chio CL, Lajiness ME, Huff RM (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45:51-60
15. Daly SA, Waddington JL (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D2-like" agonists. Neuropharmacology 32:509-510
16. Devoto P, Collu M, Muntoni AL, Pistis M, Serra G, Gessa GL, Diana M (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse 20:153-155
17. 3 receptor in the rat brain. Neuroscience 65:731-745
18. Ekman A, Eriksson E (1991) Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats. Life Sci 48:321-331
19. 3 dopamine receptor. J Pharmacol Exp Ther 268:417-426
20. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269
21. 3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 681:1-7
22. 3 receptors. Eur J Pharmacol 272:R1-R3
23. 2 receptor. Clin Neuropharmacol 18 [Suppl]:S130-S142
24. 3H]PD 128907. Psychopharmacology 128:240-247
25. Heilig M, Schlingensiepen K-H (1996) Antisense oligodeoxyneucleotides as novel neuropharmacological tools for selective expression blockade in the brain. In: Latchman D (ed) Genetic manipulation of the nervous system. Academic Press, San Diego, pp 249-268
26. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648:222-228
27. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93-96
28. 3 receptor affinities. Eur J Pharmacol 277:209-214
29. Lagerkvist S (1991) Sample splitting provides a fast and selective method for determining brain dialysate dopamine and its metabolites. In: Rollema H, Westerink B, Drijhout WJ (eds) Monitoring molecules in neuroscience. Krips Repro, Meppel, pp 136-138
30. Lai J, Crook TJ, Payne A, Lynch RM, Porreca F (1997) Antisense targeting of delta opioid receptors in NG 108-15 cells: direct correlation between oligodeoxynucleotide uptake and receptor density. J Pharmacol Exp Ther 281:589-596
31. 3 receptor mRNA and binding sites in human brain. Mol Brain Res 18:187-192
32. Landwehrmeyer B, Mengod G, Palacios JM (1993b) Differential visualization of dopamine D2 and D3 receptors sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5:145-153
33. 3 autoreceptors inhibits firing of ventral tegmental dopaminergics neurons in vivo. Eur J Pharmacol 275:R7-R9
34. 3H]Quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. J Pharmacol Exp Ther 264:991-1001
35. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159
36. 3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol 264:269-278
37. 3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797
38. 3 receptors. Mol Pharmacol 43:749-754
39. Meador-Woodruff JH (1995) Neuroanatomy of dopamine receptor gene expression: Potential substrates for neuropsychiatric illness. Clin Neuropharmacol 18 [Suppl]:S14-S24
40. 3 receptors. Eur J Pharmacol 249:R5-R6
41. Moghaddam B, Bunney BS (1989) Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53:652-654
42. Munson PJ, Rodbard D (1980) LIGAND: A versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 107:220-239
43. 2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271-11275
44. Neckers L, Whitesell L (1993) Antisense technology: biological utility and practical considerations. Am J Physiol 265:L1-L12
45. Nissbrandt H, Ekman A, Eriksson E, Heilig M (1995) Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 6:573-576
46. O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther 277:186-192
47. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
48. Piercey MF, Walker E, Feldpausch DL, Camacho-Ochoa M (1996) High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Lett 219:138-140
49. Richtand NM, Kelsoe JR, Segal DS, Kuczenski R (1995) Regional quantification of D1, D2, and D3 dopamine mRNA in rat brain using a ribonuclease protection assay. Brain Res Mol Brain Res 33:97-103
50. 3 receptor antagonist, (+)-S 14297. Eur J Pharmacol 265:175-177
51. 3 receptor: chimeric receptors delineate a role for intracellular domains. Mol Pharmacol 46:352-356
52. Sautel F, Griffon M, Lévesque D, Pilon C, Schwartz J-C, Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6:329-332
53. 3 receptors in vivo. Eur J Pharmacol 218:373-375
54. Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270
55. 2 autoreceptors in the motor actions of cocaine. Mol Pharmacol 46:51-57
56. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151
57. Spano PF, Govoni S, Trabuchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol 19:155-165
58. Steen VM, Løvlie R, MacEwan T, McCreadie RG (1997) Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 2:139-145
59. 3 receptors. Eur J Pharmacol 263:235-243
60. 3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270:475-479
61. 4 dopamine receptors in fibroblasts and dopaminergic cell lines. J Pharmacol Exp Ther 268:495-502
62. Tepper JM, Sun B-C, Martin LP, Creese I (1997) Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 17:2519-2530
63. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig, M (1993a) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528-531
64. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi CE, Reis DJ (1993b) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363:260-263
65. Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993a) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur J Pharmacol 242:151-163
66. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993b) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94:11-19
67. 2 messenger RNA. Neuroscience 55:607-612
68. Zang Z, Florijn W, Creese I (1994) Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochem Pharmacol 48:225-228
69. 2 receptors: behavioral correlates. Neurosci Lett 161:223-226
70. Zhang M, Ouagazzal A, Creese I (1995) Differential roles for dopamine "D2" receptor subtypes in locomotor activity: antisense knockout studies (abstract). Society of Neuroscience Abstracts (Vol. 21, Part 1) p 364
71. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J Pharmacol Exp Ther 271:1462-1470